Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group

Hans Erik Johnsen, Tobias W Klausen, Martin Boegsted, Stig Lenhoff, Peter Gimsing, Ilse Christiansen, Tobias Gedde-Dahl, Roald Lindås, Ulf-Henrik Mellqvist, Nordic Myeloma Study Group

    2 Citations (Scopus)

    Abstract

    An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.
    Original languageEnglish
    JournalClinical Lymphoma & Myeloma
    Volume10
    Issue number4
    Pages (from-to)290-6
    Number of pages7
    ISSN1557-9190
    DOIs
    Publication statusPublished - 1 Aug 2010

    Fingerprint

    Dive into the research topics of 'Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group'. Together they form a unique fingerprint.

    Cite this